Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $15.60 Consensus PT from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $15.60.

KLRS has been the topic of several recent research reports. Citizens Jmp cut their price target on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Morgan Stanley initiated coverage on Kalaris Therapeutics in a report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price objective on the stock. Wedbush initiated coverage on Kalaris Therapeutics in a research report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th.

Kalaris Therapeutics Stock Down 1.1%

NASDAQ:KLRS opened at $5.18 on Friday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $11.88. The company has a market capitalization of $123.23 million, a P/E ratio of -2.41 and a beta of 0.15. The stock’s fifty day moving average is $5.72 and its two-hundred day moving average is $7.53.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06. Sell-side analysts anticipate that Kalaris Therapeutics will post -2.09 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Srinivas Akkaraju bought 244,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $4.83 per share, with a total value of $1,179,969.00. Following the transaction, the director directly owned 2,224,147 shares in the company, valued at $10,742,630.01. This trade represents a 12.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 68.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $34,000. Barclays PLC purchased a new position in shares of Kalaris Therapeutics during the 4th quarter worth approximately $51,000. Johnson Financial Group Inc. purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $58,000. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Finally, WealthTrust Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 1st quarter valued at approximately $72,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.